The Oncology Institute, Inc. (TOI) Tops Q4 EPS by 5c, Offers Guidance

The Oncology Institute, Inc. (NASDAQ: TOI) reported Q4 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $71.4 million versus the consensus estimate of $64.73 million.

GUIDANCE:

The Oncology Institute, Inc. sees FY2023 revenue of $290-320 million, versus the consensus of $309 million.

For earnings history and earnings-related data on The Oncology Institute, Inc. (TOI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance